Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392

Watchlist Manager
Beijing Wantai Biological Pharmacy Enterprise Co Ltd Logo
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Watchlist
Price: 67.88 CNY -1.38% Market Closed
Market Cap: 85.9B CNY

Beijing Wantai Biological Pharmacy Enterprise Co Ltd
Operating Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Beijing Wantai Biological Pharmacy Enterprise Co Ltd
Operating Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Operating Income CAGR 3Y CAGR 5Y CAGR 10Y
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Operating Income
ÂĄ1.4B
CAGR 3-Years
22%
CAGR 5-Years
55%
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Operating Income
-ÂĄ8.8B
CAGR 3-Years
8%
CAGR 5-Years
-13%
CAGR 10-Years
N/A
Innovent Biologics Inc
HKEX:1801
Operating Income
-ÂĄ1.1B
CAGR 3-Years
0%
CAGR 5-Years
8%
CAGR 10-Years
N/A
Akeso Inc
HKEX:9926
Operating Income
ÂĄ2B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Operating Income
ÂĄ4.3B
CAGR 3-Years
-27%
CAGR 5-Years
11%
CAGR 10-Years
42%
Imeik Technology Development Co Ltd
SZSE:300896
Operating Income
ÂĄ2.1B
CAGR 3-Years
64%
CAGR 5-Years
71%
CAGR 10-Years
N/A

Beijing Wantai Biological Pharmacy Enterprise Co Ltd
Glance View

Market Cap
86.1B CNY
Industry
Biotechnology

In the bustling corridors of Beijing's biotechnology landscape, Beijing Wantai Biological Pharmacy Enterprise Co Ltd has emerged as a significant player, weaving a narrative of innovation and growth. Founded in 1991, Wantai has dedicated itself to the research, development, production, and marketing of in vitro diagnostic tests and vaccines. The company's strategic focus on infectious disease diagnostics has positioned it as a crucial contributor to public health efforts globally. With its widespread product portfolio covering respiratory diseases, sexually transmitted infections, and enteric pathogens, the firm's offerings are integral for medical professionals who rely on Wantai's reliable and precise diagnostic tools to make critical healthcare decisions. Wantai's success isn't merely confined to market presence. The company prides itself on a robust pipeline of vaccine development, targeting diseases neglected by the mainstream pharmaceutical industry. Notably, it gained significant attention during the COVID-19 pandemic for developing diagnostic tests that became pivotal in many countries' strategies to manage and track the virus. The firm's revenue streams are diversified across both domestic and international sales, bolstered by strategic partnerships and collaborations with global health organizations. By remaining at the frontier of scientific advancement and healthcare needs, Wantai thrives not just through innovation but also through its commitment to solving some of the world's most pressing health challenges.

Intrinsic Value
62.21 CNY
Overvaluation 8%
Intrinsic Value
Price

See Also

What is Beijing Wantai Biological Pharmacy Enterprise Co Ltd's Operating Income?
Operating Income
1.4B CNY

Based on the financial report for Dec 31, 2023, Beijing Wantai Biological Pharmacy Enterprise Co Ltd's Operating Income amounts to 1.4B CNY.

What is Beijing Wantai Biological Pharmacy Enterprise Co Ltd's Operating Income growth rate?
Operating Income CAGR 5Y
55%

Over the last year, the Operating Income growth was -74%. The average annual Operating Income growth rates for Beijing Wantai Biological Pharmacy Enterprise Co Ltd have been 22% over the past three years , 55% over the past five years .

Back to Top